drugset
drugset / Trial / NCT03956953

Single and Multiple Dose Pharmacokinetics of BMS-986165 in a Randomized, Double-Blind, Placebo-Controlled Study in Healthy Chinese Subjects

NCT03956953 ↗

Phase 1 Completed 135 enrolled Bristol-Myers Squibb
RandomizedParallel-groupDouble-blindTreatment

Summary

Main objective of this study is to assess BMS-986165 plasma PK following single and multiple oral doses of BMS-986165 in healthy Chinese subjects.

Timeline

Start
2019-04-04
Primary completion
2019-09-25
Completion
2019-09-25

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject CRAVACITINIB Small molecule 6 mg Oral
Subject CRAVACITINIB Small molecule 12 mg Oral

Indications

autoimmune disease